Weight Watchers Adds FDA-Approved Oral GLP-1 Foundayo for $149 Monthly Med+ Program
Weight Watchers now offers Eli Lilly’s FDA-approved oral GLP-1 Foundayo through its Med+ program, enabling adult obesity patients to access daily, injection-free treatment alongside board-certified clinician support. Self-pay pricing starts at $149 monthly for the lowest dose, and engaged Med+ members achieved 29.1% greater weight loss.
1. Foundayo Launch through Med+
Weight Watchers announced the integration of Eli Lilly’s new oral GLP-1 treatment, Foundayo (orforglipron), into its Med+ offering. This provides adults with obesity or overweight conditions a once-daily, injection-free medication option under a clinically supported program.
2. Member Access and Pricing
Clinically eligible Med+ members gain access to Foundayo alongside board-certified clinician consultations, insurance support, and the GLP-1 Success Program. Members opting for self-pay can start the lowest dose at $149 per month, with pricing scaling by dose strength.
3. Clinical Outcomes and Support Model
Data shows Med+ participants who engaged with the GLP-1 Success Program for 12 months achieved 29.1% more body weight loss compared to those without behavioral support, highlighting the value of integrated care and ongoing guidance in driving treatment efficacy.